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This review describes the recent progress in the construction of transgenic plants for vaccine producti,v 
Transgenic plants are an attractive and cost-effective alternative to microbial systems for the productior о 
proteins with pharmaceutical value. Advances in biotechnology are enabling plants to be exploitea /· 
expression of candidate vaccine antigens with the goal of using the edible plant organs for economical 
delivery of oral vaccines. It has recently been shown that genes encoding antigens of bacterial and vira< 
pathogens can be expressed in plants in a form in which they retain native immunogenic properties. 
Transgenic potato tubers expressing bacterial antigens stimulated humoral and mucosal immune response, 
when they were provided as a food. Although the utility of «edible vaccines» to prevent disease remains t< 
be established, the successful implementation of this strategy can be the first step on the way to modern 
vaccines of new generation. 
Introduction. Research on new vaccines has used 
molecular biology to identify the antigenic deter-
minants of infectious disease agents and to develop 
genetic engineering approaches to produce and deliver 
these antigens as subunit vaccines. In recent studies, 
tools of plant biotechnology have been added to these 
efforts. It has been found that transgenic plants 
provide a novel system for production of recombinant 
proteins that act as oral immunogens when the plant 
products are consumed as food. 
Many infectious agents colonize or invade epi-
thelial membranes; these include bacteria and viruses 
that are transmitted via contaminated food or water 
or by sexual contact. 
Vaccines that are effective against these in-
fections must stimulate the mucosal immune system to 
produce secretory IgA (S-IgA) at mucosal surface 
such as the gut and respiratory epithelia. In general, 
a mucosal immune response is more effectively achi-
eved by oral, rather then parenteral, antigen delivery. 
Several particulate antigens have proven to be effec-
tive oral immunogens, including live and killed micro-
organisms. By comparison with parenteral immu-
nization, oral immunization using subunit or soluble 
antigens is often inefficient at stimulating an immune 
© N. N. DOMANSKYt 1998 
response, and requires largeramounts (mg versus μ%> 
of antigen. 
Subunit vaccines based upon recombinant cell-
culture expression systems are feasible but, for con-
mercial-scale production, these systems require fei 
mentation technology and stringent purification pro 
tocols so that sufficient amounts of recombinan 
protein can be obtained for oral delivery. Even witK 
technological improvements, fermentation-based su 
bunit vaccine production may be prohibitively ex 
pensive technology for developing countries where 
novel oral vaccines are urgently needed Transgenic 
plants that express antigens in their edible tissue 
might be possible simply through consumption of a 
«edible vaccine». 
The concept of vaccine production in transgenic 
plants was introduced about 6 years ago by Charles 
Arntzen and Hugh Mason at Texas A&M University 
[1 ] greatly stimulating research in this directio! 
[ 2 - 8 ]. 
In general, research in this field falls into t>)u: 
general categories. First, experiments have been cc -
ducted to determine the capacity of plants to produce 
foreign proteins that retain antigenic determinants 
necessary for effective immunization. Second, the oral 
immunogenicity of plant-derived proteins has beer· 
evaluated with special emphasis on th< 
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immunogenicity of food samples. Third, research has 
been conducted Io find an appropriate food crop that 
could be used for both production and distribution of 
vaccines, with special emphasis on the developing 
world. 
Hepatitis B surface proteins. The first studies of 
candidate vaccine expression in transgenic plants have 
been carried out using the gene encoding hepatitis B 
surface antigen (HBsAg) [1, 3]. This protein was 
chosen because the commercially available vaccine 
and the associated human immune response have 
been very well characterized, because the structure of 
the immunogenic form of that protein was known, and 
because the availability of a cost-effective recombinant 
HBV vaccine is a high priority especially for the 
developing countries. Moreover, the existence of com-
mercially available test systems for HBV detection 
substantially simplified the procedure of HBsAg de-
tection in plant tissues. 
The envelope of hepatitis B virus (HBV) consists 
of three polypeptides which comprise the large (L), 
middle (M) and major or small (S or HBsAg) protein 
components. These three proteins are encoded in a 
large open reading frame, which is divided into preSl, 
preS2 and the S gene. The S protein or HBsAg is a 
major component of the: hepatitis B virions and 
contains 226 amino acids. The HBV M protein 
contains additional 55 amino acid residues at the 
N-terminal of the S protein, usually called the preS2 
antigen. Similarly, the L protein contains additional 
108—119 amino acids, depending on the serotype of 
the virion, at the N-terminal of the M protein [9]. 
The S gene was introduced into cells of tobacco 
[1] and potato [3] plants and individual trans-
formants were regenerated. When extracts from tran-
sgenic plant tissues were examined the presence of 
HBsAg were revealed by ELlSA using monoclonal 
antibodies directed against human-serum-derived 
HBsAg. Further examination of plant-derived HBsAg 
purified by immunoaffinity chromatography revealed 
the presence of spherical virus-like particles with an 
average size of 22 nm. These particles exhibited 
properties that were very similar to the subvi^al 
particles obtained from human serum and to the 
recombinant HBsAg which is formulated in the com-
mercial vaccine produced in yeast cells [1 ]. Im-
portantly, HBsAg in the particle form was found to be 
much more immunogenic than that in the form of the 
peptide alone [10]. 
To evaluate the immunogenicity of plant-derived 
HBsAg it was used for parenteral immunization of 
mice. Anti-HBsAg antibodies were recovered which 
reacted with authentic HBsAg from human serum. 
This was the first indication, that antigenic properties 
of the protein were maintained in transgenic plants 
Subsequently, T cells were isolated from mice im-
munized with plant-derived HBsAg. When grown in 
culture, these T cells could be activated using со α 
mercial vaccine as well as a synthetic peptide which 
mimics the «а» epitope determinant of HBsAg. in 
total, the immunology studies conducted to date show 
that the recombinant HBsAg recovered from plant 
cells retain both B and T cell epitopes [5]. 
Although recombinant HBV vaccines have shown 
that HBsAg alone is sufficient to induce a highly 
protective immunity, experiments in animals have 
highlighted the potential benefits which might resui* 
from the inclusion of the preS2 domain in anti-HBV 
vaccines [11 J. The preS2 domain is also immunogenic 
in humans and elicit anti-preS2 responses during 
natural HBV infection, which often occur prior to a ; 
other anti-HBV response [12]. For this reason, me 
HBV M protein gene (preS2 containing H BsAgj -
been recently expressed in plants 18 ] and physical 
and immunological properties of this protein wen-
evaluated [13]. These studies have demonstrated th^i 
plant cells have the capacity to not only synthesize M 
protein but also to allow it to be assembled in ar 
immunologically active form. 
To evaluate the immune response to plant-de 
rived M protein and to compare it to the response ic 
HBsAg from serum (preS2 containing HBsAg), HBV 
vaccine and plant-derived HBsAg, Balb/c mice were 
immunized intraperitoneally with corresponding an-
tigens. Kinetics of antibody responses were studies j 
to 14 weeks after primary immunization. The results 
presented in Fig. 1 indicate that both plant-derived 
HBV proteins can elicit the anti-HBsAg antibodies in 
mice and that the plant-derived M protein is nearly 
as immunogenic as the control preS2 containing 
HBsAg isolated from serum. Moreover, the presence 
of anti-preS2 antibodies in the sera of immunized 
Balb/c mice was detected in mice immunized with the 
preS2 containing proteins (Fig. 2). These result 
suggest that plant system can provide an alternative 
method of producing the HBV M protein suitable f.v 
vaccination. 
Recently, it was also shown that the plant-
derived HBV M protein given to mice by oral intu-
bation (gavage) stimulated serum antibody response 
and corresponding specific antibodies were dt tecu . 
[14]. 
Escherichia coli heat-labile enterotoxin B su 
bunit. The choice of which antigens to use in ih 
initial studies has been strongly influenced by 
desire to determine if transgenic plant materia ? 
containing foreign antigens will result in oral immu-
nization and stimulate a mucosal immune response 
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Fig. 1. Kinetics of anti-HBsAg antibody responses in Balb/c mice: 
1 — serum HBsAg; 2 - М protein; 3 — vaccine; 4 — S protein; 
5 — negative control. Mice were immunized intraperitoneally with the 
same amounts of plant-derived M and S proteins, HBsAg from serum 
and Engerix vaccine. Solid arrows indicate the time of vaccination 
(0, 2nd and 6th week). The presence of anti-HBsAg antibody were 
monitored by ELISA 
Fig. 2. Comparison of anti-preS2 antibody responses in mice. 12 
weeks post-immunization sera from individual mice immunized with 
plant-derived M protein (Ml—M6), plant-derived S protein (Si — 
S5), Engeruc vaccine (VI — V5) and HBsAg from serum (SRI — 
SR5) were tested for (he presence of anti-preS2 antibody by ELISA 
Thus, antigens with the high mucosal immune res-
ponse have been the early targets for plant based 
expression. 
The binding subunit of the heat-labile ente-
rotoxin of E. coli (LT-B) was an obvious candidate 
for evaluation in plant expression system since it has 
been extensively characterized in structural and im-
munological studies. 
The heat-labile enterotoxin (LT) from E. coli is 
a multimeric protein that is structurally, functionally 
and antigenically very similar to cholera toxin (CT). 
It was found that LT has one A subunii (LT-A) and 
a pentamer of B subunits (LT-B). Specific binding oi 
the nontoxic LT-B pentamer to the Gmi gangliosioes 
present on epithelial cell surfaces allows entry of th 
toxic LT-A subunit into cells [15]. Antibody Iil 
terference with binding of the B subunit ίο cells, lhir 
blocking toxin activity, is the basis of attempts to u < 
the B subunit as a vaccine component. Because L t 
is very similar in structure and immunological pro-
perties to the CT-B, immunization with CT-B lcaas 
to cross-protection against enterotoxigenic E. coli 
LT-B and CT-B are both potent strong oral im-
munogens. 
LT-B also has recently been expressed in plan s 
although the levels of expression were low [2 j Th* 
oral immunogenicity of recombinant LT-B was tesuc 
in mice and compared with bacterial LT-B. Vvh'к 
given orally to mice by gastric intubation, the plani-
derived antigen stimulated humoral and mucosa; 
immune responses with titers comparable to the 
bacteria-derived LT-B. In addition, the antibodies 
produced against the tobacco-derived LT-B were abl 
to neutralize LT activity, indicating the potentia' 
protective value of the immune response. 
The oral immunogenicity of unpurified recom-
binant LT-B was also assessed by feeding raw 
transgenic potato tubers to mice. After only four 
feedings of 5 g tuber samples to mice, mucosal and 
serum antibodies were recovered. No immune res-
ponse was observed in animals that were fed non-
transformed tubers. 
It should be also noted that CT and LT are 
excellent oral adjuvants, which stimulate immune 
responses against co-fed antigens at concentration., 
well below those that cause diarrhea. 
Norwalk virus capsid protein. Further evidence to 
support the concept of edible vaccines have recently 
been obtained in experiments with plant-derived Not 
walk virus capsid protein (NVCP). Norwalk virus is a 
member of the Caliciviridae family and causes epi-
demic acute gastroenteritis in humans. As in the case 
of HBV, expression of NVCP in plant cells yields .. 
protein that self-assembles in plant cells into virut 
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like particles. The plant-derived NVCP was orally 
immunogenic in mice. Extiacts of tobacco leaf exp-
ressing NVCP were given to CDl mice by gavage and 
the treated mice developed both serum IgG and 
secretory IgA specific for Norwalk virus-like particles. 
Furthermore, when potato tubers expressing NVCP 
were fed directly to mice, they developed serum IgA 
specific for Norwalk virus [7 ]. 
Vaccines for animal diseases. Edible vaccines can 
also provide efficient and humane strategies for 
disease prevention in production of companion ani-
mals, as well as feral populations. It is practically 
possible to generate vaccines against viral and bac-
terial infections by expressing corresponding antigens 
in plant tissues edible for animals. The already 
mentioned LT-B subunit is the most likely candidate 
for the first commercial vaccine, as enterotoxigenic E. 
coli strains readily infect animals as well. Admittedly, 
vaccines for animals are a more likely target for 
edible-vaccine technology in the near future than 
vaccines for human as the latter need more detailed 
inspections for safety. 
Recently, transgenic plants have been generated 
that expressed the gene encoding the glycoprotein 
(G-protein) that coats the outer surface of the rabies 
virus [6, 14 |. 
Although the immunogenicity of these material 
has yet to be evaluated, it is encouraging, to note that 
ba t containing some G~protein produced in a more 
traditional in vitro system was effective in immunizing 
raccoons orally, providing protection against «street 
virus» challenge. 
Future prospects. The research conducted to date 
has demonstrated that transgenic plants have the 
capacity to synthesize and accumulate subunit anti-
genic proteins that retain immunological properties of 
their native counterparts. In the case of HBV proteins 
and NVCP, virus-like particles accumulated in plant 
cells. It is very significant as the particulate form is 
very important in determining immunogenic pro-
perties and has greater oral immunogenicity than 
soluble proteins. 
Studies remaining to be conducted will involve 
the evaluation of dosage requirements for plant-
delivered vaccines. Successful experiments conducted 
thus far have used proteins (LT-B and NVCP) with 
very high oral immunogeniciity. It will be necessary to 
determine if other proteins, which may not be nor-
mally transmitted orally, will be as effective in 
inducing an oral response. From this point of view the 
results of the oral immunization with the plant-
derived HBV M protein are rather encouraging. 
Multi-subunit vaccines, including oral adjuvants such 
as LT or CT (or derivatives thereof), and various 
fused proteins could be also used for enhancing the 
oral response. 
It is well recognized that most food proteins do 
not trigger an immune response. In general it is due 
to the induction of a state of immune tolerance. It will 
be necessary to determine if food-based vaccines also 
would induce oral tolerance to the desired antigen If 
so, controlled use and dosage will be a requirement 
for edible vaccines. 
The type of plant material that would best serve 
as an edible vaccine also has yet to be determined 
First studies has focused primarily on tobacco and 
potato, but other plants such as corn, soybean-
bananas and others are currently under research. 
Lastly, a thorough study of the safety oi the 
future edible vaccines needs to be undei'cken. Rc 
searches in this area are likely to nci ease oui 
understanding of the basic mechanisms, which can be 
applied to the development of the new generation o. 
vaccines. 
M. M. Доманський 
Трансгенні рослини як їстівні вакцини — реальність 
та перспективи 
Резюме 
Огляд сучасних літературних даних про створ тя трансген 
них рослин для виробництва вакцин. Трансгенні рослини є дух 
привабливою та дешевою альтернативою існуючим мікря 
біологічним системам виробництва білків б.гя фармацевтики. 
Успіхи сучасної біотехнології відкрили можливість експресуво 
ти у рослинах різні антигени, що використовуються с:,я 
вакцинації, з метою використання їстівних частин рослин для 
транспорту оральних вакцин. Було продемонстровано, що 
гени, котрі кодують антигени бактеріальних та віруїні. • 
патогенів, можуть бути експресовані у рослинах із збережен-
ням їхніх природних імунологічних властивостей. Tак, бульби 
трансгенної картоплі, що експресували бактеріальні антигі 
ни, стимулювали гуморальну та мукозну імунні відповіді к<« 
використанні їх у їжу. Хоча використання їстівних вакцин для 
запобігання хвороб ще не доведене, подальшій розвиток цюго 
напряму може стати першим кроком на шляху до векцин 
нової генерації. 
Η. Н. Доманский 
Трансгенные растения как съедобные вакцины — реальность и 
перспективы 
Резюме 
Обзор современных литературных данных о создании тра 
генных растений для производства вакцин Трансгенные ρ 
тения являются весьма привлекательной и дешевой альтерна 
тивой существующим микробиологическим системам произ-
водства белков для фармацевтики. Успехи современной био-
технологии открыли возможность экспрессировать в расте-
ниях различные антигены, используемые при вакцинации, для 
применения съедобных частей растений при транспорте ора-
льных вакцин. Было продемонстрировав, что гены, кодирую-
щие антигены бактериальных и вирусных патогенов, могут 
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быть экспрессировапы в растениях с сохранением их природ-
ных иммунологических свойств. Так, клубни трансгенного 
картофеля, жспрессировавиїие бактериальные антигены, сти-
мулировали гуморальный и мукозный иммунные ответы при 
употреблении их в пищу. Хотя использование съедобных вак-
цин для предотвращения болезней еще не доказано, дальнейшее 
развитие этого направления может стать первым шагом на 
пути к созданию вакцин нового поколения. 
REFERENCES 
1. Mason Η. S., Імт D. Μ.-K., Arntzen С. J. Expression of 
hepatitis B surface antigen in transgenic plants / / Proc. Nat. 
Acacl. Sci. USA.—1992.—89.—P. 1174.5 — 11749. 
2. Hoq Τ. A., Mason H. S., Clements J. D., Arntzen C. J. Oral 
immunization with a recombinant bacterial antigen produced in 
transgenic plants 11 Science.—1995.—268.—P. 714—715. 
3. Domansky N. N.. Ehsani P., Salmanian A-H., Medvedeva T. 
Organ-specific expression of hepatitis B surface antigen in 
potato / / Biotectmol. Lett.—1995.—17.—P. 863—866. 
4. Mason H. S., Arntzen C. .1. Transgenic plants as vaccine 
production systems Il Trends Biotechriol.—1995.—13.— 
P. 388—392. 
5. Thanavala Y., Yang Y.-F., Lyons: P. et al. Immunogenicity of 
transgenic plant-derived hepatitis B surface antigen / / Proc. 
Nat. Acad Sci. USA —1995.—92,—P. 3358—2261. 
6. McGarvey P. B., Hammond J., Dienelt et al. Expression of the 
rabies virus glycoprotein in transgenic tomatoes / / Bio/Tech-
nology 1995.—13.—P. 1484— 1487. 
7. Mason H. S., Ball J. M., Shi J-J. et al. Expression of Norwalk 
virus capsid protein in transgenic tobacco and potato and its 
oral immunogenicity in mice / / Proc. Nat. Acad. Sci. USA — 
1996.—93 —P. 5335—5340. 
8. Ehsani P., Khabiri A., Domansky N. N. Polypeptides of 
hepatitis B surface antigen produced in transgenic potato / / 
Gene.—1997.—190.—P. 107—111. 
9. Tiollais P., Pourcel C., Dejean S. The hepatitis B virus 11 
Nature.—1985.—317.—P. 489—495. 
10. Cabral G. A., Marciano-Cabral F., Funk G. R. et al. Cellular 
and humoral immunity in guinea pigs to two major polypeptides 
derived from hepatitis B surface antigen Hi. Gen. Virol.— 
1978.—38 —P. 339—350. 
11. Millich D. R., Thornton G. B., Neurath et al. Enhanced 
immunogenicity of the pre-S region of hepa iis B surface 
antigen / / Science.—1985,—228.—P. 1195—1198. 
12. Petre J., Rutgers T., Hauser P. Properties of arecombinam 
yeast-derived hepatitis B surface antigen containing S preSZ 
and preSl antigenic domains / / Arch. Virol. (Suppl.).— 
1992,—24 —P. 137—141. 
13. Khabiri A., Ehsani P., Domansky N. Characterisation of the 
hepatitis B middle (M) surface protein synth чігел in trans 
genie potato plants I l Manuscript submitted. 
14. Domansky N., Khabiri A., Ehsani P. et al. Enhanced immune 
genicity of transgenic plant-derived hepatitis B middle surfaa 
antigen Il 5th Int. Congr. of Plant Мої. Biol. (Singapore, 
21—27lh September 1997).—P. 1257. 
15. Sixma T. K., Pronk S. E., Kalk K. H. et al. Crystal structure 
of a cholera toxin-related heatlabile enterotoxin from E. coli // 
Nature.—1991.—351.—P. 371—377. 
Received 26.01.98 
9 
